Blog & Learning Hub

ADA 2026 approaches with DA-1726 earning three late-breaking posters, real-world data links GLP-1 agonists to 20-35% lower dementia risk with semaglutide showing the strongest effect, FDA compounding market attracts startup investment ahead of PCAC July meeting, sermorelin officially reinstated to Category 1, and tirzepatide MASH approval marks second incretin therapy for liver disease.

Amgen's MariTide Phase 3 MARITIME program advances across six indications with Phase 2 maintenance data showing sustained weight loss on quarterly dosing. Pfizer outlines an unprecedented 20+ obesity trial program for 2026 with ADA data imminent. AVA6103 becomes the first FAP-targeted sustained-release PDC to enter clinical trials for solid tumors. A landmark JACC meta-analysis of 99,599 patients confirms GLP-1 drugs slash cardiovascular events across all demographics. Plus: TRIUMPH-2 diabetes readout approaches as next major industry catalyst.

Retatrutide TRIUMPH-1 delivers 28.3% weight loss at 80 weeks and 30.3% at 104 weeks — the largest ever recorded in a Phase 3 obesity trial. A landmark meta-analysis of 90,000+ patients confirms GLP-1 drugs slash heart attacks, strokes, and cardiovascular death. Oral Ozempic tablets launch nationwide at $149/month. The global peptide-based health market is forecast for explosive long-term growth. Plus: AI peptide design competition unites 300 researchers, and the PCAC July countdown continues.

DA-1726 delivers 9.1% weight loss in just 8 weeks in Phase 1, challenging early-phase benchmarks. Cotadutide's MASH trial data establishes the dual agonist mechanistic template. Pemvidutide secures FDA Breakthrough Therapy Designation with Phase 3 initiation planned. Over 100 GLP-1-based compounds now in development as dual agonism emerges as the dominant next-generation strategy.

Aleniglipron ACCESS II 44-week data sets new oral GLP-1 efficacy record at 16.3% weight loss with FDA Phase 3 green light. CagriSema REIMAGINE 2 confirms dual-pathway superiority over semaglutide in type 2 diabetes. TRIUMPH-1 retatrutide readout imminent with 30%+ weight loss projected. Global peptide market forecast to reach $11.2B by 2035 as AI compresses discovery timelines.

Navepegritide (Yuviwel) becomes the first once-weekly CNP analog FDA-approved for achondroplasia in children. Retatrutide TRANSCEND-T2D-1 reports 2.0% A1C reduction and 16.8% weight loss. New tesamorelin meta-analysis confirms targeted visceral fat reduction. PCAC July 23–24 meeting approaches with public comment deadline July 9 for BPC-157, TB-500, KPV, and MOTS-c.

Viking's oral VK2735 achieves 12.2% weight loss at 13 weeks with novel maintenance data at ECO 2026. Retatrutide TRIUMPH-1 pivotal readout due Q2–Q3 2026 with analyst projections above 30%. AI-discovered antimicrobial peptides deliver 79% hit rate from 863K candidate sequences. Oral Wegovy sees rapid real-world adoption with 36% new-to-GLP-1 patients. Peptide-drug conjugates achieve 85% tumor-specific delivery in Phase II.

Stanford's AI-discovered BRP peptide suppresses appetite via hypothalamus without GLP-1 side effects. A Nature-published quintuple agonist targets 5 receptors simultaneously. CagriSema delivers 20.4% weight loss in pivotal NEJM trial. Queensland's PTP-r destroys white fat cells through mitochondrial disruption. FDA approves first-ever oral GLP-1 pill for obesity ($149/month).

MBX Biosciences reports Phase 1 data showing 7% mean weight loss at 8 weeks for MBX 4291 with only 1 mild GI event and zero nausea or vomiting, plus nominates MBX 5765 as first-ever GLP-1/GIP/GCG/DACRA quad agonist. ECO 2026 features ASC47 data showing 111.8% greater weight loss when added to semaglutide. Boehringer Ingelheim advances BI 3034701 (GLP-1/GIP/NPY2 triple agonist) to Phase 2. GEP-44 triple agonist targeting GLP-1/PYY-Y1/PYY-Y2 progresses through IND-enabling studies.

CagriSema achieves 23% weight loss but fails to match tirzepatide in head-to-head REDEFINE 4 trial. A landmark Lancet Psychiatry study links GLP-1 drugs to a 42% lower risk of worsening depression and anxiety. NIH-funded Nature paper reveals oral GLP-1 drugs suppress cravings by reaching the brain's central amygdala. ECO 2026 opens in Istanbul with Ascletis monthly peptide data and VK2735 oral presentations. PCAC July 2026 agenda confirmed for BPC-157, TB-500, KPV, and MOTS-c.

Survodutide SYNCHRONIZE-1 Phase 3 reports 16.6% weight loss at 76 weeks. ECO 2026 in Istanbul features Viking's VK2735 oral data and Ascletis's once-monthly ASC36/ASC35/ASC37 pipeline. The FDA proposes permanently excluding semaglutide, tirzepatide, and liraglutide from 503B compounding. And a Molecular Metabolism paper shows GIP/glucagon dual agonism achieves weight loss without GLP-1 — potentially eliminating GI side effects.

The FDA confirms its July 23–24 PCAC meeting will review BPC-157, TB-500, KPV, MOTS-c, Semax, Epithalon, and DSIP for 503A compounding eligibility. A landmark NEJM trial shows tirzepatide outperforms semaglutide by 6.5 percentage points in weight loss. Viking completes VANQUISH-2 enrollment for VK2735, and researchers identify CAP-GDF15 as a new appetite-suppressing peptide from the GDF15 propeptide region.

Structure Therapeutics' aleniglipron posts up to 15.3% weight loss in Phase 2, readying Phase 3 to compete with Foundayo. Retatrutide's pivotal TRIUMPH-1 obesity readout is expected any day. Pemvidutide's MASH data reaches The Lancet with Breakthrough Therapy Designation. And AI-designed antimicrobial peptides advance toward clinics.

FDA approves the first oral macrocyclic peptide (icotrokinra) for psoriasis, China greenlights the world's first cAMP-biased GLP-1 RA (ecnoglutide) for weight management, FOXO4-DRI senolytic peptide research expands to human chondrocyte models, and Novo Nordisk launches Phase 3 for amycretin's dual GLP-1/amylin agonism.

A landmark Nature paper introduces the first quintuple receptor agonist (GLP-1/GIP/PPARα/γ/δ) for obesity, GDF-15 receptor agonists gain momentum as a non-GLP-1 weight loss mechanism, and apelin/APJ cardiovascular peptides advance toward clinical candidates.

Semaglutide's EVOKE/EVOKE+ Alzheimer's trials show no cognitive benefit at 104 weeks despite reducing CSF p-tau181, Viking Therapeutics completes VANQUISH-2 Phase 3 enrollment for VK2735, the FDA opens the BPC-157 public comment docket ahead of the July 23 PCAC meeting, and Aivocode's CAQK peptide prepares for its first human trial after definitive preclinical TBI data.

Survodutide hits 16.6% weight loss in its Phase 3 SYNCHRONIZE-1 debut, mazdutide becomes the first dual GCG/GLP-1 agonist approved anywhere with dual China NMPA approvals, orforglipron proves it can maintain injectable weight loss in ATTAIN-Maintain, Pfizer discontinues danuglipron after a liver safety signal, and the July 2026 PCAC meeting agenda takes shape.

Amgen's once-monthly MariTide advances into phase 3 MARITIME trials with up to 20% weight loss and no plateau, GLP-1 drugs are being repositioned for Alzheimer's and Parkinson's disease, the STEER analysis finds semaglutide outperforms tirzepatide on cardiovascular outcomes, and a Nature GWAS identifies a GLP1R variant predicting individual weight loss response.

The FDA formally removes 12 peptides from Category 2 ahead of July PCAC hearings, LL-37 derivative research achieves improved stability and efficacy, dihexa produces measurable synaptogenesis in non-human primates, pentosan polysulfate shows 6-month disease modification in OA, and DSIP fusion peptides cross the blood-brain barrier.

Novo Nordisk's amycretin enters Phase 3 for obesity with 22% weight loss from Phase 1b/2a, BPC-157 gains new muscle regeneration data ahead of July PCAC review, retatrutide's TRANSCEND-T2D-1 confirms 36.6 lbs weight loss, and AACR 2026 showcases peptide-drug conjugate breakthroughs in cancer therapy.

Eli Lilly's Foundayo (orforglipron) becomes the first oral non-peptide GLP-1 approved for weight loss, CagriSema shows superiority over semaglutide alone in REIMAGINE-2, semaglutide enters Alzheimer's Phase 3 trials, tirzepatide reduces sleep apnea events, and the FDA peptide reclassification moves forward.

Viking Therapeutics completes VANQUISH-2 Phase 3 enrollment, a Nature GWAS identifies a GLP1R variant predicting drug response, CleaveNet AI designs tumor-targeted peptides, and Hims & Hers surges on FDA peptide review and Novo Nordisk settlement.

Eli Lilly's Foundayo (orforglipron) ships as the first non-peptide GLP-1 pill. Stanford discovers GLP-1 resistance in 10% of people. CagriSema REDEFINE trials published in NEJM. Medicare GLP-1 Bridge launches July 2026. FDA PCAC docket deadline updated to July 22.

Semaglutide 7.2 mg (Wegovy HD) launches with 20.7% weight loss data. Retatrutide Phase 3 delivers 28.7% loss plus osteoarthritis relief. Eloralintide introduces a new amylin-based drug class. VK2735 oral dual agonist enters Phase 3 despite tolerability questions.

A Stanford AI tool discovers BRP — a natural appetite peptide without GLP-1 side effects. Pfizer's monthly GLP-1 shot enters Phase 3 planning. Pemvidutide earns Breakthrough Therapy status for MASH. Oral Wegovy launches. The obesity peptide pipeline is expanding faster than ever.

A comprehensive look at the biggest peptide developments of 2026 so far — from FDA approvals and reclassifications to breakthrough clinical trial results and the rise of longevity peptides.

With search interest up over 1,000% year-over-year, GHK-Cu has emerged as the most talked-about peptide of 2026. Here's why the science backs up the hype.

In February 2026, the FDA reclassified 14 peptides back to Category 1 compounding status. Here's what this means for researchers, clinicians, and patients.

A deep dive into mitochondrial-targeted peptides and molecules — how they work, what research shows, and why cellular energy is central to aging science.

An overview of peptides and hormones used in fertility medicine — from established treatments to emerging research compounds.

An educational look at melanocortin-based tanning peptides — how they work, their regulatory status, and important safety considerations.

A comprehensive guide to GLP-1 receptor agonists — how they work, what sets them apart, and where the science is heading.

An overview of peptides studied for immune system modulation, from approved medications to emerging research.

An evidence-based look at GHK-Cu, one of the most researched peptides in dermatology and anti-aging science.

A deep dive into bioavailability — why it matters for peptides and how it affects research outcomes.

Exploring what research says about peptides studied for sleep regulation, including DSIP and others.

An educational overview of growth hormone secretagogues, how they work, and what research has found.

Separating science from hype — addressing the most common misconceptions about peptides.

A side-by-side comparison of two popular recovery peptides, examining what research says about each.

A high-level overview of safety considerations when researching peptides, including quality indicators and red flags.

What does 'low,' 'medium,' or 'high' evidence mean? Learn how to interpret research quality when evaluating peptides.

An accessible introduction to peptides — what they are, how they differ from proteins, and why researchers are interested in them.